BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 37108840)

  • 1. Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta.
    Guibourdenche J; Leguy MC; Pidoux G; Hebert-Schuster M; Laguillier C; Anselem O; Grangé G; Bonnet F; Tsatsaris V
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
    Hu Z; Liu X; Li L; Jia C; Li D; Liu R
    Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
    Liao S; Wang Y; Ye G
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.
    Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG
    Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hCG in screening for aneuploidy: a possible role for its glycoforms?
    Brun S; Leguy MC; Bruneel A; Fournier T; Anselem O; Guibourdenche J
    Placenta; 2014 Jun; 35(6):425-7. PubMed ID: 24731729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
    Spencer K; Liao AW; Skentou H; Cicero S; Nicolaides KH
    Prenat Diagn; 2000 Jun; 20(6):495-9. PubMed ID: 10861716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.